Verona Pharma can make a real difference to the COPD market believes CEO Jan-Anders Karlsson

Runtime: 09:23

 

Innovative Therapies for Respiratory Care

Innovative Therapies for Respiratory Care

Exciting Phase 2 results with ensifentrine dry powder inhaler formulation

Exciting Phase 2 results with ensifentrine dry powder inhaler formulation

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us